Elixir Medical announced positive data demonstrating the benefit of its DynamX coronary bioadaptor system in target lesion failure (TLF). Data highlighted the success of DynamX compared to Medtronic's Resolute Onyx zotarolimus drug-eluting stent … [Read More...] about Elixir Medical has positive data for drug-eluting bioadaptive implant
Main Content
Drug Tech
Today on Drug Delivery Business
- Elixir Medical has positive data for drug-eluting bioadaptive implant
- Insulcloud wins FDA nod to bring smart insulin pen cap tech to U.S.
- Tidepool, Abbott collab on data integration for FreeStyle Libre
- Senseonics announces $16M registered direct offering
- Dexcom submits 15-day CGM to FDA, beats Street in Q3
- January AI unveils glucose prediction app with enhanced meal scanner tech
- Ypsomed, BD collab on self-injection systems for high-viscosity biologics
Sponsored Content
Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Manufacturing automation is crucial to achieving the precision, quality, and volume required in the medical device industry. Advanced robotics, AI, modular designs, and wireless technology offer the … [Read More...] about Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Featured Posts
Insulcloud wins FDA nod to bring smart insulin pen cap tech to U.S.
By Sean Whooley
Insulcloud today announced its strategic expansion into the U.S. following FDA clearance for its Insulclock CAP smart device. Madrid, Spain-based Insulcloud designed the device to monitor patient use of disposable insulin pens in real-time, … [Read More...] about Insulcloud wins FDA nod to bring smart insulin pen cap tech to U.S.
Tidepool, Abbott collab on data integration for FreeStyle Libre
By Sean Whooley
Tidepool today announced a new data integration with Abbott for the company's FreeStyle Libre continuous glucose monitors (CGMs). The companies aim to deliver cloud-to-cloud integration for an automatic stream of data from patients using Abbott's … [Read More...] about Tidepool, Abbott collab on data integration for FreeStyle Libre
Senseonics announces $16M registered direct offering
By Sean Whooley
Senseonics (NYSE:SENS) announced today that it entered into a definitive agreement to offer $16 million in common stock. Germantown, Maryland-based Senseonics plans to offer more than 45.7 million shares of common stock. It priced the shares at … [Read More...] about Senseonics announces $16M registered direct offering
Dexcom submits 15-day CGM to FDA, beats Street in Q3
By Sean Whooley
Dexcom (Nasdaq:DXCM) announced that, following the conclusion of the third quarter, it submitted its 15-day G7 CGM to the FDA. G7, the company's latest-generation continuous glucose monitor (CGM), presently has approval for a 10-day wear … [Read More...] about Dexcom submits 15-day CGM to FDA, beats Street in Q3
Luna Diabetes launches trial for ‘world’s smallest insulin patch pump’
By Sean Whooley
Luna Diabetes announced that it launched its pivotal trial for Luna, the company's miniature automated insulin delivery system. The company describes the system — designed to transform nighttime glucose management — as the world's smallest patch … [Read More...] about Luna Diabetes launches trial for ‘world’s smallest insulin patch pump’
Know Labs appoints new chief science, technology officers
By Sean Whooley
Know Labs (NYSE:KNW) announced today that it appointed a new chief science officer (CSO) and interim chief technology officer (CTO). The company picked Dominic Klyve to serve as CSO, while John Cronin takes up the interim CTO … [Read More...] about Know Labs appoints new chief science, technology officers
ViCentra wins CE mark for Kaleido insulin pump
By Sean Whooley
ViCentra announced that it received CE mark approval for its Kaleido insulin pump under European Medical Device Regulation (EU MDR). Utrecht, The Netherlands-based ViCentra aims to deliver high-quality, user-friendly solutions for people with … [Read More...] about ViCentra wins CE mark for Kaleido insulin pump
SpyGlass Pharma shares positive data for drug-eluting intraocular lens
By Sean Whooley
SpyGlass Pharma released 18-month follow-up data highlighting the potential of its intraocular lens (IOL)-based drug delivery platform. Data came from a first-in-human study of 23 patients with glaucoma or ocular hypertension. They received the … [Read More...] about SpyGlass Pharma shares positive data for drug-eluting intraocular lens
Ypsomed increases auto-injector production in Germany
By Sean Whooley
Ypsomed announced today that it opened a new production hall at its German site in Schwerin to increase auto-injector production. The Burgdorf, Switzerland-based company said its expansion enables an increase in production capacity to meet growing … [Read More...] about Ypsomed increases auto-injector production in Germany
NIH launches effort to combat type 2 diabetes in young people
By Sean Whooley
The National Institutes of Health (NIH) launched a nationwide consortium to address the rise in youth diagnosed with type 2 diabetes. According to a press release, NIH expects that trend — which it observed over the past two decades — to continue … [Read More...] about NIH launches effort to combat type 2 diabetes in young people
In case you missed it
- Glooko announces CEO transition with $100M financing
- Trinity Biotech completes pre-pivotal study of next-gen CGM
- BD partners with ten23 health on prefilled syringe manufacturing
- Medtronic recalls some MiniMed automated insulin delivery systems with battery issues
- MannKind has more positive inhaled insulin data
- Qnovia wins FDA nod for nicotine inhaler as smoking cessation therapy
- Senseonics, Ascensia launch Eversense 365 year-long CGM in the U.S.
- Stevanato Group expands large-volume drug delivery offerings
- Vivani can begin first-in-human GLP-1 implant trial in Australia following regulatory approval
- Dexcom, Retta, Beyond Type 2 team up to raise glucose awareness
- Ypsomed reports positive outcomes with automated insulin delivery for maternal health
- Tandem wins clearance for t:slim X2 pump with Eli Lilly fast-acting insulin in Europe
- Phillips Medisize to buy inhaled drug delivery device maker Vectura from Philip Morris
- Class action suit targets Abbott FreeStyle Libre amid claims of data sharing
- BD launches new prefillable syringe, expands platform capacity
Clinical Trials
Elixir Medical has positive data for drug-eluting bioadaptive implant
Elixir Medical announced positive data demonstrating the benefit of its DynamX coronary bioadaptor system in target lesion failure (TLF). Data highlighted the success of DynamX compared to Medtronic’s Resolute Onyx zotarolimus drug-eluting stent (DES). The study looked at complex patient populations within the INFINITY-SWEDEHEART randomized controlled trial. Data included an analysis of patients with acute […]
Luna Diabetes launches trial for ‘world’s smallest insulin patch pump’
Luna Diabetes announced that it launched its pivotal trial for Luna, the company’s miniature automated insulin delivery system. The company describes the system — designed to transform nighttime glucose management — as the world’s smallest patch pump. Luna delivers micro-doses of insulin while the user sleeps. According to the company, it offers the “simplest onboarding […]
SpyGlass Pharma shares positive data for drug-eluting intraocular lens
SpyGlass Pharma released 18-month follow-up data highlighting the potential of its intraocular lens (IOL)-based drug delivery platform. Data came from a first-in-human study of 23 patients with glaucoma or ocular hypertension. They received the IOL implant at the time of cataract surgery. The company reported a consistent sustained reduction of intraocular pressure (IOP) across all […]
NIH launches effort to combat type 2 diabetes in young people
The National Institutes of Health (NIH) launched a nationwide consortium to address the rise in youth diagnosed with type 2 diabetes. According to a press release, NIH expects that trend — which it observed over the past two decades — to continue moving forward. It aims to advance understanding of the biologic, social, and environmental […]
Clearside Biomedical’s drug-device combo study meets endpoints
Clearside Biomedical (Nasdaq:CLSD) today announced that the ODYSSEY study of its drug-device combination achieved its primary and secondary outcomes. Alpharetta, Georgia-based Clearside develops the SCS Microinjector suprachoroidal injection device. It enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to […]